Uni-Rare Study will improve clinical understanding of more I…
Born from the Foundation Fighting Blindness, the RD (Retinal Degeneration) Fund was created to help accelerate life-changing outcomes for people with retinal degenerations through direct mission related investments in therapeutic companies. The mission of the Foundation Fighting Blindness is to rapidly drive the research that will lead to preventions, treatments and cures for retinal degenerative diseases – including retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. Together, these blinding conditions affect more than 200 million people throughout the world.
The RD Fund is changing how the world treats blinding retinal diseases.
Click here to download the January 2022 Outcomes & Outlook Report.
IN THE NEWS
11/08/2022
Nacuity Pharmaceuticals Expands Board of Directors with Appointment…
Managing director of the Retinal Degeneration Fund joins boa…
11/08/2022
Atsena Therapeutics Expands Leadership Team with Appointment of Lis…
Biotech leader brings extensive experience in finance, busin…
10/12/2022
Ascidian Therapeutics Launches to Rewrite RNA
ATP incubated and built Ascidian with $50 million in Series …
10/03/2022
Atsena Therapeutics Announces Positive Results from Phase I/II Clin…
ATSN-101 demonstrated clinically meaningful improvements in …
09/27/2022
Opus Genetics Expands Board of Directors with Appointment of Global…
RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE…
09/15/2022
RD Fund Participates in a €75 Million Series B for SparingVision
Proceeds to fund first, in-human trials of breakthrough gene…
08/12/2022
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Pa…
- In line with corporate strategy update in April, ProQR to f…
07/27/2022
Atsena Therapeutics Announces Opening of New Office and Laboratory…
World-class facility supports the company’s growth, and disc…
07/21/2022
Opus Genetics Expands its Leadership Team
Vikram Arora, Ph.D., DABT, appointed Vice President of Non-C…
07/21/2022
RD Fund Announces New Chair, and Expansion of Board of Directors
RD Fund Board member and seasoned ophthalmology leader Adrie…
07/11/2022
Opus Genetics to Present at OIS Retina Innovation Summit 2022
Opus Genetics, a patient-first gene therapy company developi…